Standout Papers

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple m... 2011 2026 2016 2021 647
  1. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study (2011)
    Philippe Moreau, Halyna Pylypenko et al. The Lancet Oncology
  2. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma (2018)
    Meletios Α. Dimopoulos, Dominik Dytfeld et al. New England Journal of Medicine
  3. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study (2020)
    Meletios Α. Dimopoulos, Hang Quach et al. The Lancet

Immediate Impact

1 by Nobel laureates 11 from Science/Nature 75 standout
Sub-graph 1 of 19

Citing Papers

Decoding Toll-like receptors: Recent insights and perspectives in innate immunity
2024 Standout
Natural killer cell therapies
2024 StandoutNature
1 intermediate paper

Works of Xavier Leleu being referenced

MYD88 L265P mutation in Waldenstrom macroglobulinemia
2013
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism
2007

Author Peers

Author Last Decade Papers Cites
Xavier Leleu 6687 6254 2847 4297 449 11.0k
Daniel J. DeAngelo 8805 6062 3832 4155 438 15.9k
Asher Chanan‐Khan 5549 5332 2839 4014 362 10.5k
Frits van Rhee 9687 6427 1924 6217 413 13.7k
Pellegrino Musto 5497 4241 2385 3409 381 9.4k
Ramón García‐Sánz 5332 3890 2984 3516 344 9.3k
Wendy Stock 5950 3463 2245 3563 457 11.8k
Jean‐Luc Harousseau 10396 8236 2510 6599 317 15.0k
Dieter Hoelzer 7148 4532 4499 4508 321 16.1k
Mario Boccadoro 10751 8129 2133 7326 468 15.8k
Hervé Dombret 13182 7064 3576 3977 369 18.4k

All Works

Loading papers...

Rankless by CCL
2026